"""
Question: 1101

Evidence: The molecular epidemiologic profile of HIV-1 in Suriname was determined through protease (PR) and reverse transcriptase (RT) sequences obtained from HIV-1 strains collected from 100 drug-naive HIV-1-infected persons. This study reveals that the HIV-1 epidemic in Suriname is still characterized by a low TDRM rate (1%) and a low level of subtype diversity.

Rationale: The abstract and introduction state that this study was conducted to investigate the molecular epidemiologic profile and present the first published data on TDR in HIV-1-infected individuals in Suriname, indicating the data was previously unpublished.

Answer: Yes
"""

"""
Question: 1102

Evidence: The GenBank accession numbers for the sequences are KX390878 to KX390977. PR and RT nucleotide sequences obtained were aligned using MEGA5 software with known group M reference sequences pooled from the HIV-1 database.

Rationale: The paper explicitly states that sequences were obtained and analyzed, and provides GenBank accession numbers for the HIV sequences, confirming that HIV sequences are reported.

Answer: Yes
"""

"""
Question: 1103

Evidence: This study allowed us to document the circulating HIV-1 subtypes in Suriname and present the first published data on TDR in HIV-1-infected individuals in Suriname. The study population consisted of ARV-naive adult HIV-1-positive persons.

Rationale: The paper describes a molecular epidemiology study of clinical samples from treatment-naive patients. There is no mention of in vitro passage experiments being conducted.

Answer: No
"""

"""
Question: 1104

Evidence: The presence of drug resistance-associated mutations (DRMs) in PR and RT was detected and drug susceptibility was predicted using the French ANRS HIV-1 genotypic drug resistance algorithm version 25. According to the French ANRS algorithm, version 25, September 2015. Major resistance mutations are in bold.

Rationale: The paper reports genotypic drug resistance predictions using an algorithm, but does not mention any in vitro antiretroviral susceptibility testing being performed.

Answer: No
"""

"""
Question: 2101

Evidence: The GenBank accession numbers for the sequences are KX390878 to KX390977.

Rationale: The paper explicitly provides GenBank accession numbers for the sequenced HIV isolates in the "Sequence Data" section.

Answer: Yes
"""

"""
Question: 2102

Evidence: The GenBank accession numbers for the sequences are KX390878 to KX390977. Phylogenetic analyses together with the CPR tool showed that all RT sequences (n = 95) clustered with subtype B.

Rationale: The paper reports GenBank accession numbers for sequences obtained from clinical HIV isolates from treatment-naive patients, not laboratory HIV isolates.

Answer: Yes
"""

"""
Question: 2103

Evidence: The GenBank accession numbers for the sequences are KX390878 to KX390977.

Rationale: The paper explicitly states the GenBank accession numbers in the "Sequence Data" section.

Answer: KX390878 to KX390977
"""

"""
Question: 2202

Evidence: Table 3. Characteristics of the Samples Presenting Drug Resistance Mutations Conferring Resistance and/or Possible Resistance to ARV. For example, sample KX390962 has V75M in RT and G16E, V77I in PROT.

Rationale: Table 3 provides detailed lists of mutations for individual sequenced HIV isolates that showed drug resistance mutations.

Answer: Yes
"""

"""
Question: 2301

Evidence: The molecular epidemiologic profile of HIV-1 in Suriname was determined through protease (PR) and reverse transcriptase (RT) sequences obtained from HIV-1 strains.

Rationale: The paper specifically states that HIV-1 strains were studied throughout the text.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: Subtype determination revealed that most viruses were of subtype B (94.9%) in both PR and RT genomic regions, followed by B/D recombinants (5.1%).

Rationale: The results section clearly states the subtype distribution of the sequenced viruses.

Answer: Subtype B (94.9%) and B/D recombinants (5.1%)
"""

"""
Question: 2303

Evidence: The molecular epidemiologic profile of HIV-1 in Suriname was determined through protease (PR) and reverse transcriptase (RT) sequences obtained from HIV-1 strains.

Rationale: The paper explicitly states that protease (PR) and reverse transcriptase (RT) genes were sequenced.

Answer: Protease (PR) and reverse transcriptase (RT)
"""

"""
Question: 2304

Evidence: The molecular epidemiologic profile of HIV-1 in Suriname was determined through protease (PR) and reverse transcriptase (RT) sequences obtained from HIV-1 strains. PR and RT sequences were analyzed for polymorphisms.

Rationale: The paper reports sequencing and analysis of HIV pol gene regions, specifically protease and reverse transcriptase.

Answer: Yes
"""

"""
Question: 2401

Evidence: Suriname is located on the northeastern coast of South America, between Guyana and French Guiana. One hundred one HIV-1-infected adult naive patients were recruited in Paramaribo.

Rationale: The paper clearly states that the study was conducted in Suriname, specifically in the capital Paramaribo and surrounding areas.

Answer: Suriname (Paramaribo and surrounding areas)
"""

"""
Question: 2402

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs.

Rationale: The methods section explicitly states when the samples were collected.

Answer: August to October 2009
"""

"""
Question: 2502

Evidence: The amplified products were sent to Beckman Coulter Genomics for direct sequencing on both strands. Chromatograms were verified, analyzed, and interpreted using CEQ 2000XL software.

Rationale: The description of sequencing methodology using direct sequencing on both strands and analysis of chromatograms is characteristic of Sanger sequencing.

Answer: Yes
"""

"""
Question: 2503

Evidence: The amplified products were sent to Beckman Coulter Genomics for direct sequencing on both strands. Chromatograms were verified, analyzed, and interpreted using CEQ 2000XL software.

Rationale: The paper describes traditional Sanger sequencing methodology with no mention of next-generation sequencing technologies.

Answer: No
"""

"""
Question: 2504

Evidence: For genotyping, RNA was reverse transcribed to cDNA and amplified for partial RT and protease genes using the ANRS consensus sets of primers. The amplified products were sent to Beckman Coulter Genomics for direct sequencing on both strands.

Rationale: The methodology describes direct sequencing of amplified products without any mention of cloning prior to sequencing.

Answer: No
"""

"""
Question: 2505

Evidence: For genotyping, RNA was reverse transcribed to cDNA and amplified for partial RT and protease genes using the ANRS consensus sets of primers. The amplified products were sent to Beckman Coulter Genomics for direct sequencing on both strands.

Rationale: The paper describes bulk PCR amplification and direct sequencing, not single genome sequencing or limiting dilution approaches.

Answer: No
"""

"""
Question: 2506

Evidence: For genotyping, RNA was reverse transcribed to cDNA and amplified for partial RT and protease genes using the ANRS consensus sets of primers. The amplified products were sent to Beckman Coulter Genomics for direct sequencing on both strands.

Rationale: The methodology describes direct sequencing of PCR products without any mention of molecular cloning steps.

Answer: No
"""

"""
Question: 2601

Evidence: Blood samples (2 × 5 ml) were drawn by venous puncture in EDTA tubes. Plasma was separated and stored at −80°C until RNA extraction for viral load (VL) measurement and genotyping.

Rationale: The methods clearly state that plasma was used for RNA extraction and genotyping, indicating plasma HIV sequencing was performed.

Answer: Yes
"""

"""
Question: 2602

Evidence: Plasma was separated and stored at −80°C until RNA extraction for viral load (VL) measurement and genotyping. RNA was isolated from 1 ml of plasma with the Nuclisens EasyMag.

Rationale: The paper specifically mentions using plasma for RNA extraction and sequencing, with no mention of PBMC isolation or DNA sequencing.

Answer: No
"""

"""
Question: 2603

Evidence: One hundred one HIV-1-infected adult naive patients were recruited. One patient was excluded for genotyping due to a VL below 100 copies/ml. Successful amplification was observed for 99 PR and 95 RT genes.

Rationale: The results indicate that 100 out of 101 recruited patients had plasma virus sequencing attempted, with successful amplification in most cases.

Answer: 100
"""

"""
Question: 2604

Evidence: Plasma was separated and stored at −80°C until RNA extraction for viral load (VL) measurement and genotyping. RNA was isolated from 1 ml of plasma.

Rationale: The paper only describes plasma virus sequencing and does not mention PBMC virus sequencing at all.

Answer: 0
"""

"""
Question: 2605

Evidence: The VL ranged from 25 to 10^6 copies/ml. One patient was excluded for genotyping due to a VL below 100 copies/ml.

Rationale: The paper reports viral load measurements and excluded one patient with very low VL, indicating sequences were obtained from individuals with active HIV replication.

Answer: Yes
"""

"""
Question: 2606

Evidence: Plasma was separated and stored at −80°C until RNA extraction for viral load (VL) measurement and genotyping. RNA was isolated from 1 ml of plasma.

Rationale: The paper explicitly states that RNA was extracted from plasma for sequencing, indicating viral RNA sequencing rather than proviral DNA sequencing.

Answer: No
"""

"""
Question: 2701

Evidence: One hundred one HIV-1-infected adult naive patients were recruited in Paramaribo. The mean age was 38 years (range, 18-62) for women and 39 (range, 23-58) for men.

Rationale: The paper specifically states that only adult patients (age range 18-62) were recruited, with no mention of infants or children.

Answer: No
"""

"""
Question: 2702

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs.

Rationale: The paper describes an observational cross-sectional study, not a clinical trial.

Answer: No
"""

"""
Question: 2703

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs.

Rationale: The paper describes an observational study of treatment-naive patients, not a clinical trial.

Answer: No
"""

"""
Question: 3101

Evidence: One hundred one HIV-1-infected adult naive patients were recruited in Paramaribo. One patient was excluded for genotyping due to a VL below 100 copies/ml.

Rationale: The paper states that 101 individuals had samples obtained for HIV sequencing, though one was subsequently excluded.

Answer: 101
"""

"""
Question: 3102

Evidence: One hundred one HIV-1-infected adult naive patients were recruited. One patient was excluded for genotyping due to a VL below 100 copies/ml. Successful amplification was observed for 99 PR and 95 RT genes.

Rationale: While 101 patients were recruited, one was excluded from genotyping, and successful amplification rates varied between PR and RT genes.

Answer: No
"""

"""
Question: 4101

Evidence: The study population consisted of ARV-naive adult HIV-1-positive persons. This study allowed us to document the circulating HIV-1 subtypes in Suriname and present the first published data on TDR in HIV-1-infected individuals in Suriname.

Rationale: The paper explicitly states that all study participants were ARV-naive.

Answer: Yes
"""

"""
Question: 4102

Evidence: The study population consisted of ARV-naive adult HIV-1-positive persons living in Paramaribo and the surrounding areas.

Rationale: The paper clearly states that only ARV-naive individuals were included in the study.

Answer: No
"""

"""
Question: 4103

Evidence: The study population consisted of ARV-naive adult HIV-1-positive persons. Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs.

Rationale: The paper explicitly states that only ART-naive individuals were included, with no ART-experienced participants.

Answer: No
"""

"""
Question: 4104

Evidence: One hundred one HIV-1-infected adult naive patients were recruited in Paramaribo. The study population consisted of ARV-naive adult HIV-1-positive persons.

Rationale: The paper clearly states that all 101 recruited patients were ART-naive.

Answer: 101
"""

"""
Question: 4105

Evidence: The study population consisted of ARV-naive adult HIV-1-positive persons. Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs.

Rationale: The paper explicitly states that all individuals were ART-naive, providing complete ART history information for all participants.

Answer: Yes
"""

"""
Question: 4201

Evidence: According to the WHO list for surveillance of DRMs, the overall prevalence of TDR in Suriname was 1% with only one isolate bearing a DRM to the NRTI Stavudine.

Rationale: The paper explicitly reports the prevalence of transmitted HIV drug resistance (TDR) as 1%.

Answer: Yes
"""

"""
Question: 4202

Evidence: According to the WHO list for surveillance of DRMs, the overall prevalence of TDR in Suriname was 1% with only one isolate bearing a DRM to the NRTI Stavudine.

Rationale: Since all patients were treatment-naive, the transmitted drug resistance reported is equivalent to pretreatment HIV drug resistance.

Answer: Yes
"""

"""
Question: 4301

Evidence: The study population consisted of ARV-naive adult HIV-1-positive persons. Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs.

Rationale: The paper explicitly states that all individuals were ARV-naive and had not received any antiretroviral drugs.

Answer: None (all patients were ARV-naive)
"""

"""
Question: 4302

Evidence: The study population consisted of ARV-naive adult HIV-1-positive persons. The common first-line ARV regimens use a combination of two nucleoside and one nonnucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs).

Rationale: The paper describes current treatment regimens in Suriname but states that all study participants were ARV-naive and had not received any antiretroviral drugs, including integrase inhibitors.

Answer: No
"""

"""
Question: 4303

Evidence: The study population consisted of ARV-naive adult HIV-1-positive persons. Patients who fail this first line of treatment are switched to a protease inhibitor (PI)-based regimen with a backbone of NRTIs.

Rationale: While the paper mentions that PIs are used as second-line treatment in Suriname, all study participants were ARV-naive and had not received any antiretroviral drugs.

Answer: No
"""

"""
Question: 4304

Evidence: The study population consisted of ARV-naive adult HIV-1-positive persons. Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs.

Rationale: Since all individuals were ARV-naive, none had received any ART regimens.

Answer: NA
"""

"""
Question: 4305

Evidence: The study population consisted of ARV-naive adult HIV-1-positive persons. Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs.

Rationale: Since all individuals were ARV-naive, they were INSTI-naive by definition, as they had not received any antiretroviral drugs.

Answer: Yes
"""

"""
Question: 4403

Evidence: The study population consisted of ARV-naive adult HIV-1-positive persons. Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs.

Rationale: All individuals were ARV-naive and had not received any ART regimens.

Answer: 0
"""

"""
Question: 4404

Evidence: The study population consisted of ARV-naive adult HIV-1-positive persons. Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs.

Rationale: All individuals were ARV-naive and had not received any ART regimens.

Answer: 0
"""

"""
Question: 4405

Evidence: The study population consisted of ARV-naive adult HIV-1-positive persons. Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs.

Rationale: Since all individuals were ARV-naive, they all received the same number of ART regimens (zero).

Answer: Yes
"""

"""
Question: 4406

Evidence: The study population consisted of ARV-naive adult HIV-1-positive persons. Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs.

Rationale: All individuals were ARV-naive and had not received any ART regimens.

Answer: Yes
"""

"""
Question: 4501

Evidence: The study population consisted of ARV-naive adult HIV-1-positive persons. Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs.

Rationale: All individuals were ARV-naive and had not received any antiretroviral drugs, including dolutegravir.

Answer: 0
"""

"""
Question: 4502

Evidence: The study population consisted of ARV-naive adult HIV-1-positive persons. Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs.

Rationale: All individuals were ARV-naive and had not received any antiretroviral drugs, including darunavir.

Answer: 0
"""

"""
Question: 5101

Evidence: With regard to the presence of DRMs in RT, one isolate out of 95 (1.05%) exhibited a major DRM (V75M). According to the WHO list for surveillance of DRMs, the overall prevalence of TDR in Suriname was 1% with only one isolate bearing a DRM.

Rationale: The paper reports that only one individual had a major drug resistance mutation (V75M).

Answer: 1
"""

"""
Question: 5102

Evidence: The presence of drug resistance-associated mutations (DRMs) in PR and RT was detected and drug susceptibility was predicted using the French ANRS HIV-1 genotypic drug resistance algorithm.

Rationale: The paper only sequenced protease and reverse transcriptase genes, not integrase, and no INSTI-resistance"""
Question: 5102

Evidence: The presence of drug resistance-associated mutations (DRMs) in PR and RT was detected and drug susceptibility was predicted using the French ANRS HIV-1 genotypic drug resistance algorithm.

Rationale: The paper only reports sequencing of the protease (PR) and reverse transcriptase (RT) genes. Integrase was not sequenced, so no INSTI-resistance mutations could be reported.

Answer: 0
"""

"""
Question: 5103

Evidence: With regard to the presence of DRMs in RT, one isolate out of 95 (1.05%) exhibited a major DRM (V75M), conferring resistance to the NRTI Stavudine (d4T).

Rationale: The paper reports one major NRTI resistance mutation (V75M), but this confers resistance to Stavudine (d4T), not Tenofovir (TDF). No TDF-resistance mutations (such as K65R) are mentioned.

Answer: 0
"""

"""
Question: 5104

Evidence: The presence of drug resistance-associated mutations (DRMs) in PR and RT was detected and drug susceptibility was predicted using the French ANRS HIV-1 genotypic drug resistance algorithm.

Rationale: The paper only sequenced protease and reverse transcriptase genes. Integrase was not sequenced, so no INSTI-resistance mutations are reported.

Answer: None reported
"""

"""
Question: 6101

Evidence: The presence of drug resistance-associated mutations (DRMs) in PR and RT was detected and drug susceptibility was predicted using the French ANRS HIV-1 genotypic drug resistance algorithm version 25.

Rationale: The paper reports genotypic drug resistance testing using an algorithm, but does not mention any phenotypic susceptibility testing being performed.

Answer: No phenotypic susceptibility test was used
"""

"""
Question: 6102

Evidence: The presence of drug resistance-associated mutations (DRMs) in PR and RT was detected and drug susceptibility was predicted using the French ANRS HIV-1 genotypic drug resistance algorithm.

Rationale: The paper only reports genotypic resistance testing and does not mention any IC50 or IC90 values, which are associated with phenotypic testing.

Answer: No
"""

"""
Question: 6103

Evidence: The presence of drug resistance-associated mutations (DRMs) in PR and RT was detected and drug susceptibility was predicted using the French ANRS HIV-1 genotypic drug resistance algorithm.

Rationale: The paper only reports genotypic resistance testing and does not mention any IC50 fold change values, which are associated with phenotypic testing.

Answer: No
"""

"""
Question: 6104

Evidence: The presence of drug resistance-associated mutations (DRMs) in PR and RT was detected and drug susceptibility was predicted using the French ANRS HIV-1 genotypic drug resistance algorithm.

Rationale: The paper only describes genotypic drug resistance testing using an algorithm and does not mention any phenotypic susceptibility assays being performed.

Answer: No phenotypic susceptibility assay was used
"""

"""
Question: 6105

Evidence: PR and RT sequences were analyzed for polymorphisms, which were defined as any amino acid change compared to the B subtype consensus sequence HXB2.

Rationale: The paper focuses on genotypic analysis of polymorphisms and drug resistance mutations, with no mention of replication capacity assays.

Answer: No
"""

"""
Question: 6106

Evidence: The presence of drug resistance-associated mutations (DRMs) in PR and RT was detected and drug susceptibility was predicted using the French ANRS HIV-1 genotypic drug resistance algorithm.

Rationale: The paper only reports genotypic resistance predictions and does not mention any phenotypic drug susceptibility testing being performed on specific drugs.

Answer: No drugs were tested using phenotypic susceptibility assays
"""

"""
Question: 7101

Evidence: This study allowed us to document the circulating HIV-1 subtypes in Suriname and present the first published data on TDR in HIV-1-infected individuals in Suriname. The study population consisted of ARV-naive adult HIV-1-positive persons.

Rationale: The paper describes sequencing of natural HIV-1 isolates from treatment-naive patients. There is no mention of site-directed mutagenesis being performed.

Answer: No
"""

"""
Question: 7102

Evidence: This study allowed us to document the circulating HIV-1 subtypes in Suriname and present the first published data on TDR in HIV-1-infected individuals in Suriname. The study population consisted of ARV-naive adult HIV-1-positive persons.

Rationale: The paper describes a molecular epidemiology study of clinical samples. There is no mention of in vitro passage experiments being conducted.

Answer: No
"""